Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.76 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.56 |
| ▸ | AHR | P35869 | 3/20 | 0.54 |
| ▸ | CMA1 | P23946 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850050 | 1.00 | PDE3B (0.76) | PDE3BPDE3ACRBNAHRCMA1 | |
| SCHEMBL23143482 | 0.86 | PDE3B (1.00) | PDE3BPDE3AAHRCYP1A2CYP11B1 | |
| SCHEMBL16321811 | 0.84 | PDE3B (0.55) | PDE3BPDE3ACRBNAHRCMA1 | |
| SCHEMBL6746651 | 0.83 | CYP11B1 (0.55) | PDE3BPDE3ACRBNAHRCMA1 | |
| SCHEMBL731334 | 0.83 | PIK3CA (0.59) | PDE3BPDE3ACRBNCYP1A2CYP11B1 | |
| SCHEMBL3659028 | 0.83 | CYP11B1 (0.79) | PDE3BPDE3ACRBNCYP1A2CYP11B1 | |
| SCHEMBL29899622 | 0.83 | CYP11B1 (0.79) | PDE3BPDE3ACRBNCYP1A2CYP11B1 | |
| SCHEMBL23143591 | 0.83 | CMA1 (0.55) | PDE3BPDE3ACRBNAHRCMA1 | |
| SCHEMBL23143561 | 0.83 | PDE3B (0.54) | PDE3BPDE3ACRBNAHRCMA1 | |
| SCHEMBL23143575 | 0.83 | PDE3B (0.54) | PDE3BPDE3ACRBNAHRCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542274-B1 | Therapeutic compounds and methods of use thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2023-01-03 | — | — | US | disclosed |
| US-11542274-B1 | Therapeutic compounds and methods of use thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2023-01-03 | — | — | US | disclosed |
| CN-114929670-A | Therapeutic compounds and methods of use thereof | 新加坡科技研究局 | 2022-08-19 | — | — | CN | disclosed |
| EP-4034526-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Agency for Science, Technology and Research (A*STAR) (SG) | 2022-08-03 | — | — | EP | disclosed |
| US-20210147441-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2021-05-20 | — | — | US | disclosed |
| US-20210147441-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2021-05-20 | — | — | US | disclosed |
| WO-2021061053-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021061053-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2021-04-01 | — | — | WO | disclosed |
| EP-3010914-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202493-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | WO | disclosed |
| US-6689806-B1 | MODULATING PROTEIN KINASES AND RELATED SIGNAL TRANSDUCTION PATHWAYS | SUGEN, INC. | 2004-02-10 | — | — | US | disclosed |
| EP-1165513-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056709-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147441-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | UBQLN2, TXNRD1, TXNRD2 | PDE3B 3649/4885PDE3A 3826/4885CRBN 342/4885 |
| US-11542274-B1 | Therapeutic compounds and methods of use thereof | MDM2, SUMO2, XIAP | PDE3B 4185/4885PDE3A 4198/4885CRBN 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.